Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 5/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 2/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
| ▸ | CCKAR | P32238 | 1/20 | 0.41 |
| ▸ | CCKBR | P32239 | 1/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.40 |
| ▸ | ITGAV | P06756 | 1/20 | 0.40 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.39 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 2/20 | 0.38 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7167643 | 0.90 | ITGB3 (0.42) | ITGB3ITGA2BITGAVUSP2GAA | |
| SCHEMBL7167872 | 0.90 | IDO1 (0.46) | ITGB3ITGA2BIDO1ACEPTPN1 | |
| SCHEMBL7164986 | 0.89 | IDO1 (0.44) | ITGB3ITGA2BIDO1ACEPTPN1 | |
| SCHEMBL7169224 | 0.89 | ITGB3 (0.39) | ITGB3ITGA2BITGB1ITGAVITGB5 | |
| SCHEMBL7159936 | 0.89 | ITGB3 (0.43) | ITGB3ITGA2BIDO1ACEPTPN1 | |
| SCHEMBL7164960 | 0.88 | IDO1 (0.48) | ITGB3ITGA2BIDO1ACEPTPN1 | |
| SCHEMBL7169163 | 0.87 | IDO1 (0.43) | ITGB3ITGA2BIDO1ACEPTPN1 | |
| SCHEMBL7160880 | 0.87 | ITGB3 (0.41) | ITGB3ITGA2BITGAVUSP2GAA | |
| SCHEMBL7160937 | 0.86 | IDO1 (0.43) | ITGB3ITGA2BIDO1ACEPTPN1 | |
| SCHEMBL7163742 | 0.85 | ITGB3 (0.54) | ITGB3ITGA2BIDO1ITGAVCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6559144-B2 | Integrin inhibitors used to treat circulatory disorders, for thrombosis, myocardial infarct, coronary heart disease, arteriosclerosis, osteoporosis, pathological processes maintained or propagated by angiogenesis and tumor therapy | MERCK PATENT GESELLSCHAFT MIT (DE) | 2003-05-06 | — | — | US | disclosed |
| EP-0964856-B1 | BICYCLIC AMINO ACIDS | MERCK PATENT GMBH (DE) | 2002-10-09 | — | — | EP | disclosed |
| US-20010021709-A1 | Bicyclic amino acids | MERCK PATENT GESELLSCHAFT MIT BESCHRANKT PATENTS (DE) | 2001-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010021709-A1 | Bicyclic amino acids | ITGA1, ITGB1, ITGB2 | ITGB3 5/4885ITGA2B 14/4885IDO1 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.